Description

Emoxypine Succinate Powder

Emoxypine Succinate
CAS Number	2364-75-2
Molar Mass	137.182 g·mol−1
Chemical Formula	C8H11NO
IUPAC Name	2-Ethyl-6-methyl-3-hydroxypyridine

Introduction

Emoxypine Succinate Powder is an advanced research product meticulously designed for scientific investigations in various fields, including neurology and pharmacology. This powdered formulation contains Emoxypine Succinate, a compound that has garnered interest for its potential effects on neurological functions. It is imperative to emphasize that this product is exclusively intended for research purposes and should not be considered for human consumption.

Key Characteristics

Emoxypine Succinate Powder is characterized by its high purity and versatility. The finely milled powder is synthesized and quality-tested to meet the highest standards, ensuring its reliability in research applications.

Research Applications

Researchers and scientists can employ Emoxypine Succinate Powder for a range of research areas, including studies on memory enhancement, nervousness, and anxiety, and its potential applications in acute ischemic stroke models. The powdered form offers precision in dosing and application, making it a valuable tool for the comprehensive exploration of Emoxypine Succinate’s potential in these domains.

Research Benefits

Memory Enhancement

Emoxypine Succinate has been investigated for its potential to enhance memory and cognitive function. Research studies have explored its effects on memory retention and recall, and researchers can further investigate its mechanisms and implications in cognitive enhancement.

Nervousness and Anxiety

Some preliminary research suggests that Emoxypine Succinate may have anxiolytic effects, potentially influencing nervousness and anxiety levels. Researchers can investigate its impact on neurotransmitter systems and its potential in alleviating anxiety-related symptoms.

Acute Ischemic Stroke

Emoxypine Succinate has also been studied for its potential application in acute ischemic stroke. Research has suggested that it may have neuroprotective properties. Researchers can explore its impact on brain injury and recovery in acute ischemic stroke models.

Summary

Emoxypine Succinate Powder is a research product meticulously designed for scientific investigations in neurology and pharmacology. With its high purity and versatile powdered form, it offers a versatile option for a wide range of research applications. Researchers can explore the potential benefits of Emoxypine Succinate in memory enhancement, anxiety reduction, and neuroprotection following acute ischemic stroke with the support of existing scientific literature.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. ANTIOXIDANT MEXIDOL. The main neuropsychotropic effects and the mechanism of action. Author: T.A.Voronina Publication: Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, RussiaT. Voronina, Published 2013, Medicine. [Read More].
2. Chefranova ZhIu, Makotrova TA, Udachin VA, Koledintseva EV. [Efficacy of mexidol in the combination with thrombolytic therapy in patients with ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(4):49-52. Russian. PMID: 22810741. [Read More].